RenovoRx, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 9.89 million compared to USD 6.32 million a year ago. Basic loss per share from continuing operations was USD 1.09 compared to USD 1.21 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.13 USD | -2.59% |
|
-13.08% | -50.66% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-50.66% | 27.78M | |
+15.20% | 122B | |
+19.67% | 113B | |
+18.95% | 26.49B | |
-23.86% | 19.4B | |
-19.03% | 16.24B | |
-20.90% | 15.4B | |
-46.14% | 15.15B | |
+63.85% | 14.93B | |
+4.49% | 13.52B |
- Stock Market
- Equities
- RNXT Stock
- News RenovoRx, Inc.
- RenovoRx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022